�����a(ch��n)Ʒ���S��

ZM 39923 HClZM 39923 HCl,JAK3 Inhibitor IV,
zm 39923 hcl is an jak1/3 inhibitor with pic50 of 4.4/7.1, almost no activity to jak2 and modestly potent to egfr; also found to be sensitive to transglutaminase.
���•r(sh��)�g:2025-06-07
KB-R7943KB-R7943,KB-R7943 mesylate,
kb-r7943 mesylate is a widely used inhibitor of the reverse na+/ca2+ exchanger (ncxrev) with ic50 of 5.7��2.1 ��m.
���•r(sh��)�g:2025-06-07
PI-103PI-103,PI103,PI 103
pi-103 is a potent, cell-permeable, atp-competitive inhibitor of pi3k family members (ic50s: 2/3/3/15/30/23 nm for p110��/��/��/��, mtor, and dna-pk).
���•r(sh��)�g:2025-06-07
IMD 0354IMD 0354,IKK2 Inhibitor V,
imd-0354 is an ikk�� inhibitor and inhibits i��b�� phosphorylation in nf-��b pathway.
���•r(sh��)�g:2025-06-07
SB-334867SB-334867,SB334867,SB 334867
sb-334867 is a selective orexin-1 (ox1) receptor antagonist.
���•r(sh��)�g:2025-06-07
A-674563A-674563,A674563,A 674563
a-674563 is an akt1 inhibitor with ki of 11 nm, modest potent to pka and >30-fold selective for akt1 over pkc.
���•r(sh��)�g:2025-06-07
TCS 359TCS 359,FLT3 Inhibitor,
tcs 359 is a potent flt3 inhibitor with ic50 of 42 nm.
���•r(sh��)�g:2025-06-07
KRN-633KRN-633,KRN633,KRN 633
krn-633 is an effective vegfr inhibitor. the ic50s of krn-633 for vegfr1, vegfr2, and vegfr3 is 170, 160 and 125 nm, respectively.
���•r(sh��)�g:2025-06-07
CanertinibCanertinib,PD-183805,CI-1033
canertinib is a pan-erbb tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by pet.
���•r(sh��)�g:2025-06-07
DibenzazepineDibenzazepine,DBZ,YO-01027
yo-01027 is a potent ��-secretase inhibitor.
���•r(sh��)�g:2025-06-07
Remodelin hydrobromideRemodelin hydrobromide,Remodelin,Remodelin HBR
remodelin hbr salt is a novel potent and selective inhibitor of the acetyl-transferase protein nat10.
���•r(sh��)�g:2025-06-07
PimasertibPimasertib,MSC1936369B,AS703026
pimasertib is an orally bioavailable small-molecule inhibitor of mek1 and mek2 (mek1/2) with potential antineoplastic activity.
���•r(sh��)�g:2025-06-07
Skepinone-LSkepinone-L,CBS3830,
skepinone-l is a selective p38 mitogen-activated protein kinase inhibitor.
���•r(sh��)�g:2025-06-07
PHA-665752PHA-665752,PHA665752,PHA 665752
pha-665752 is an effective, specific and atp-competitive c-met inhibitor (ic50: 9 nm), >50-fold selectivity for c-met than stks or rtks.
���•r(sh��)�g:2025-06-07
Rucaparib PhosphateRucaparib Phosphate,PF-01367338 phosphate,AG-014699 phosphate
rucaparib is an inhibitor of parp (ki: 1.4 nm for parp1) that is used in clinical therapy to sensitize cancer cells to chemotherapy.
���•r(sh��)�g:2025-06-07
JNJ-7706621JNJ-7706621,JNJ7706621,JNJ 7706621
jnj-7706621 is a potent aurora kinase inhibitor, and also inhibits cdk1 and cdk2.
���•r(sh��)�g:2025-06-07
SemagacestatSemagacestat,LY450139,
semagacestat (ly450139) is a ��-secretase blocker for a��42/a��40/a��38 (ic50: 10.9/12.1/12.0 nm) and also inhibits notch signaling (ic50: 14.1 nm).
���•r(sh��)�g:2025-06-07
MubritinibMubritinib,TAK-165,
mubritinib (tak-165) is a potent inhibitor of her2/erbb2 with ic50 of 6 nm.
���•r(sh��)�g:2025-06-07
VerdinexorVerdinexor,KPT-335,
verdinexor (kpt-335), a specific xpo1/crm1 inhibitor, are orally bioavailable.
���•r(sh��)�g:2025-06-07
CEP-33779CEP-33779,CEP33779,CEP 33779
cep-33779 is a novel and selective inhibitor of jak2 with an ic50 of 1.8��0.6 nm.
���•r(sh��)�g:2025-06-07
TepotinibTepotinib,EMD-1214063,MSC2156119
tepotinib is an inhibitor of met tyrosine kinase with potential antineoplastic activity.
���•r(sh��)�g:2025-06-07
PralatrexatePralatrexate,Folotyn,10-Propargyl-10-deazaaminopterin
pralatrexate is a folate analogue inhibitor of dihydrofolate reductase (dhfr) exhibiting high affinity for reduced folate carrier-1 (rfc-1) with antineoplastic and immunosuppressive activities.
���•r(sh��)�g:2025-06-07
BLZ945BLZ945
blz945 is an orally active, effective and specific csf-1r inhibitor (ic50: 1 nm), >1000-fold selective against its closest receptor tyrosine kinase homologs.
���•r(sh��)�g:2025-06-07
HSP990HSP990,NVP-HSP990,
nvp-hsp990 (hsp990) is an effective and specific hsp90��/�� inhibitor (ic50: 0.6 /0.8 nm).
���•r(sh��)�g:2025-06-07
TivantinibTivantinib,ARQ 197,
tivantinib is an orally bioavailable small molecule inhibitor of c-met with potential antineoplastic activity.
���•r(sh��)�g:2025-06-07
Bleomycin SulfateBleomycin Sulfate,NSC125066,Blenoxane
bleomycin sulfate, a glycopeptide antibiotic, is an anticancer agent for squamous cell carcinomas (scc). in ut-scc-19a cells, the ic50 of bleomycin sulfate is 4 nm.
���•r(sh��)�g:2025-06-07
FostamatinibFostamatinib,R788,
fostamatinib(ic50 of 41 nm), which is a prodrug of the active metabolite r406, is a syk inhibitor. it does not work on lyn.
���•r(sh��)�g:2025-06-07
NifursolNifursol
nifursol is a livestock feed additive and antiobiotic used to prevent the growth of histomonas.
���•r(sh��)�g:2025-06-07
DoxercalciferolDoxercalciferol,1.alpha.-Hydroxyvitamin D2,1��-hydroxyvitamin D2
doxercalciferol is a synthetic vitamin d2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.
���•r(sh��)�g:2025-06-07
SelisistatSelisistat,EX-527,SEN0014196
ex 527 is an effective and specific sirt1 inhibitor (ic50: 38 nm) and shows >200-fold selectivity against sirt2/3.
���•r(sh��)�g:2025-06-07
YM201636YM201636
ym201636 (ic50=33 nm), a specific pikfyve inhibitor, is less effective to p110�� and insensitive to fabl, which is yeast orthologue.
���•r(sh��)�g:2025-06-07
DarapladibDarapladib,SB-480848,
darapladib(ic50=0.25 nm) is a substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-a2 (lp-pla2).
���•r(sh��)�g:2025-06-07
phosphorylcholinephosphorylcholine,Phosphocholine chloride,
phosphorylcholine is an antigenic cell-surface component found on many commensal and pathogenic bacteria that reside in the upper airway.
���•r(sh��)�g:2025-06-07
Cerdulatinib hydrochlorideCerdulatinib hydrochloride,Cerdulatinib,PRT062070
cerdulatinib (prt-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with ic50 of 12 nm/6 nm/8 nm/0.5 nm and 32 nm for jak1/jak2/jak3/tyk2 and syk, respectively. also inhibits 19 other tested kinases with ic50 less than 200 nm.
���•r(sh��)�g:2025-06-07
VS-5584VS-5584,VS5584,VS 5584
vs-5584 is a pan-pi3k/mtor kinase inhibitor.
���•r(sh��)�g:2025-06-07
EntospletinibEntospletinib,GS-9973,
entospletinib ��ic50= 7.7 nm��is a specific syk inhibitor��which is orally bioavailable.
���•r(sh��)�g:2025-06-07
Torin 2Torin 2
torin 2(ic50=0.25 nm), a specific and effective mtor inhibitor, is the 800-fold greater specific activity for mtor than pi3k and improves pharmacokinetic properties. the ec50 of torin 2 for atm/atr/dna-pk inhibition is 28 nm/35 nm/118 nm, respectively.
���•r(sh��)�g:2025-06-07
GKT137831GKT137831,Setanaxib,
gkt137831 is a potent, specific dual nadph oxidase (nox1/4) inhibitor.
���•r(sh��)�g:2025-06-07
CabotegravirCabotegravir,S/GSK1265744,GSK-1265744
cabotegravir (gsk744, gsk1265744) is a long-acting hiv integrase inhibitor and inhibits the hiv-1 integrase catalyzed strand transfer reaction (ic50: 3.0 nm).
���•r(sh��)�g:2025-06-07
GNF-5837GNF-5837,GNF5837,GNF 5837
gnf-5837 is a specific, and orally bioavailable pan-trk inhibitor for trka/trkb (ic50: 8/12 nm).
���•r(sh��)�g:2025-06-07
PretomanidPretomanid,(S)-PA 824,PA-824
pa-824, a nitroimidazole, is used as an anti-tuberculosis drug for tuberculosis with mic less than 2.8 ��m.
���•r(sh��)�g:2025-06-07
JNJ-38877605JNJ-38877605,JNJ38877605,JNJ 38877605
jnj-38877605 is an atp-competitive c-met inhibitor (ic50: 4 nm), 600-fold selective for c-met than 200 other tyrosine and serine-threonine kinases.
���•r(sh��)�g:2025-06-07
MK-2461MK-2461,MK2461,MK 2461
mk-2461 is a novel atp-competitive multitargeted inhibitor of activated c-met with a mean ic50 of 2.5 nm.
���•r(sh��)�g:2025-06-07
AZD7762AZD7762
azd7762, an effective and specific inhibitor of chk1��ic50=5 nm��, is equally potent against chk2 and less potent against cam, yes, fyn, lyn, hck and lck.
���•r(sh��)�g:2025-06-07
SapitinibSapitinib,AZD-8931,
azd8931, a reversible, atp competitive inhibitor of egfr(ic50=4 nm), erbb2(ic50=3 nm) and erbb3(ic50=4 nm), is more effective over gefitinib or lapatinib against nsclc cell, 100-fold more specific for the erbb family over mnk1 and flt.
���•r(sh��)�g:2025-06-07
CP-673451CP-673451,CP673451,CP 673451
cp-673451 is a specific inhibitor of pdgfr��/�� (ic50: 10/1 nm) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.
���•r(sh��)�g:2025-06-07
BelnacasanBelnacasan,VX-765,
vx-765 is an orally active il-converting enzyme/caspase-1 inhibitor.
���•r(sh��)�g:2025-06-07
NeflamapimodNeflamapimod,VX-745,
vx-745, a specific and effective inhibitor of p38��(ic50=10 nm), is 22-fold greater specificity against p38�� and no inhibition activity to p38��.
���•r(sh��)�g:2025-06-07
AnidulafunginAnidulafungin,LY303366,Eraxis
anidulafungin (ly303366) is an echinocandin derivative used as an antifungal drug. it inhibits glucan synthase activity.
���•r(sh��)�g:2025-06-07
AZD6482AZD6482,KIN 193,
azd 6482 is a potent and selective p110�� inhibitor with ic50 of 0.69 nm and a pi3k�� inhibitor with ic50 of 10 nm.
���•r(sh��)�g:2025-06-07

���®a(ch��n)Ʒ

���T�x���� Һ��ɫ�V�x ����ɫ�V�x ԭ�ӟɹ���V�x ��Ҋ(ji��n)�ֹ���Ӌ(j��) Һ�|(zh��)“(li��n)�Ãx ����ԇ�(y��n)�C(j��) ���Ӌ(j��)��PHӋ(j��)�� �x�ęC(j��) �����x�ęC(j��) ����x�ęC(j��) �����@΢�R �����@΢�R ��(bi��o)��(zh��n)���|(zh��) ����ԇ��